{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:44:35Z","timestamp":1778125475295,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.pnpbp.2021.110480","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T12:24:47Z","timestamp":1637670287000},"page":"110480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder"],"prefix":"10.1016","volume":"114","author":[{"given":"Gernot","family":"Fugger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Bartova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Dold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Zanardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kautzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Souery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Mendlewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Rujescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.pnpbp.2021.110480_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15071425","article-title":"Epidemiology of suicide and the psychiatric perspective","volume":"15","author":"Bachmann","year":"2018","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110480_bb0010","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","article-title":"Results of the european group for the study of resistant depression (GSRD) - basis for further research and clinical practice","volume":"20","author":"Bartova","year":"2019","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0015","first-page":"1","article-title":"Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines","author":"Bauer","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110480_bb0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/acps.12878","article-title":"Comparison of guidelines for the treatment of unipolar depression: a focus on pharmacotherapy and neurostimulation","volume":"137","author":"Bayes","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110480_bb0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/appi.ajp.2009.09020186","article-title":"Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study","volume":"167","author":"Blier","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110480_bb0030","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16r10749","article-title":"Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis","volume":"79","author":"Bschor","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"10128","key":"10.1016\/j.pnpbp.2021.110480_bb0035","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110480_bb0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.comppsych.2007.06.005","article-title":"Medication use patterns and two-year outcome in first-admission patients with major depressive disorder with psychotic features","volume":"48","author":"Craig","year":"2007","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0045","article-title":"Pharmacological interventions for treatment-resistant depression in adults","volume":"12","author":"Davies","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110480_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13651501.2016.1248852","article-title":"Evidence-based pharmacotherapy of treatment-resistant unipolar depression","volume":"21","author":"Dold","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"12","key":"10.1016\/j.pnpbp.2021.110480_bb0055","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.euroneuro.2016.10.005","article-title":"Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers \u2013 a pharmacoepidemiological cross-sectional multicenter study","volume":"26","author":"Dold","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110480_bb0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000477770","article-title":"Dose escalation of antidepressants in unipolar depression: a meta-analysis of double-blind, randomized controlled trials","volume":"86","author":"Dold","year":"2017","journal-title":"Psychother. Psychosom."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110480_bb0065","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ijnp\/pyy009","article-title":"Major depression and the degree of suicidality: results of the european group for the study of resistant depression (GSRD)","volume":"2","author":"Dold","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.pnpbp.2021.110480_bb0070","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.euroneuro.2018.10.003","article-title":"Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study","volume":"28","author":"Dold","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110480_bb0075","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m12090","article-title":"Psychotic features in patients with major depressive disorder - a report from the European Group for the Study of Resistant Depression","volume":"80","author":"Dold","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0080","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.euroneuro.2020.09.636","article-title":"Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study","volume":"41","author":"Dold","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110480_bb0085","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/ijnp\/pyaa034","article-title":"Treatment response of add-on esketamine nasal spray in resistant major depression in relation to add-on second-generation antipsychotic treatment","volume":"23","author":"Dold","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110480_bb0090","doi-asserted-by":"crossref","first-page":"110285","DOI":"10.1016\/j.pnpbp.2021.110285","article-title":"Melancholic features in major depression - a European multicenter study","volume":"110","author":"Dold","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0095","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jpsychires.2019.03.008","article-title":"Recall accuracy for the symptoms of a major depressive episode among clinical trial participants","volume":"116","author":"Dunlop","year":"2019","journal-title":"J. Psychiatr. Res."},{"issue":"12","key":"10.1016\/j.pnpbp.2021.110480_bb0100","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110480_bb0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4088\/JCP.11r07324","article-title":"Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment","volume":"73","author":"Farahani","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110480_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw066","article-title":"A neuroscience-based nomenclature (NbN) for psychotropic agents","volume":"19","author":"Frazer","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110480_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109638","article-title":"Major depression and comorbid diabetes - findings from the European Group for the study of resistant depression","volume":"94","author":"Fugger","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-244X-12-143","article-title":"Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment","volume":"12","author":"Garcia-Toro","year":"2012","journal-title":"BMC Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110480_bb0125","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4088\/JCP.13m08675","article-title":"National trends in second-generation antipsychotic augmentation for nonpsychotic depression","volume":"75","author":"Gerhard","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110480_bb0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/YIC.0000000000000196","article-title":"Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression","volume":"33","author":"Gobbi","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"22","key":"10.1016\/j.pnpbp.2021.110480_bb0135","first-page":"2179","article-title":"Trial of SAGE-217 in patients with major depressive disorder. Reply","volume":"381","author":"Gunduz-Bruce","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2021.110480_bb0140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jad.2015.03.021","article-title":"Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials","volume":"180","author":"Hayasaka","year":"2015","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110480_bb0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/15622970701691503","article-title":"Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder","volume":"11","author":"Kasper","year":"2010","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0155","first-page":"1","article-title":"Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance","author":"Kasper","year":"2020","journal-title":"World J. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110480_bb0160","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/mp.2016.120","article-title":"HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition","volume":"22","author":"Keller","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0165","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jad.2016.12.013","article-title":"The effect of treatment as usual on major depressive disorder: a meta-analysis","volume":"210","author":"Kolovos","year":"2017","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110480_bb0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41398-019-0460-3","article-title":"Prognosis and improved outcomes in major depression: a review","volume":"9","author":"Kraus","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110480_bb0175","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.4088\/JCP.13m08843","article-title":"Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study","volume":"75","author":"Lin","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110480_bb0180","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/0706743716664885","article-title":"Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults","volume":"62","author":"MacQueen","year":"2017","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2021.110480_bb0185","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2020.02.023","article-title":"The identification, assessment and management of difficult-to-treat depression: an international consensus statement","volume":"267","author":"McAllister-Williams","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110480_bb0190","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110480_bb0195","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jama.2017.8036","article-title":"Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial","volume":"318","author":"Mohamed","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0200","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110480_bb0205","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110480_bb0210","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1586\/14737175.6.7.1049","article-title":"Combination pharmacotherapy in unipolar depression","volume":"6","author":"Ng","year":"2006","journal-title":"Expert. Rev. Neurother."},{"issue":"Suppl. 6","key":"10.1016\/j.pnpbp.2021.110480_bb0215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4088\/JCP.8133su1c.03","article-title":"Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder","volume":"70","author":"Papakostas","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2021.110480_bb0220","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4088\/JCP.14077su1c.03","article-title":"Identifying patients with depression who require a change in treatment and implementing that change","volume":"77","author":"Papakostas","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2021.110480_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101700","article-title":"Do atypical antipsychotics have antisuicidal effects? A hypothesis-generating overview","volume":"17","author":"Pompili","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110480_bb0230","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4088\/JCP.v69n0805","article-title":"Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study","volume":"69","author":"Reeves","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0235","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jad.2019.04.018","article-title":"Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders","volume":"252","author":"Rhee","year":"2019","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110480_bb0240","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jsr.12594","article-title":"European guideline for the diagnosis and treatment of insomnia","volume":"26","author":"Riemann","year":"2017","journal-title":"J. Sleep Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110480_bb0245","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e318248581b","article-title":"Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis","volume":"32","author":"Rocha","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110480_bb0250","doi-asserted-by":"crossref","first-page":"110157","DOI":"10.1016\/j.pnpbp.2020.110157","article-title":"New agents and perspectives in the pharmacological treatment of major depressive disorder","volume":"106","author":"Sanches","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0255","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpsychires.2021.02.020","article-title":"Intranasal esketamine: from origins to future implications in treatment-resistant depression","volume":"137","author":"Sanders Benjamin","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110480_bb0260","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.euroneuro.2012.02.006","article-title":"European group for the study of resistant depression (GSRD)--where have we gone so far: review of clinical and genetic findings","volume":"22","author":"Schosser","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl. 20","key":"10.1016\/j.pnpbp.2021.110480_bb0265","article-title":"The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110480_bb0270","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4088\/JCP.v68n0713","article-title":"Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study","volume":"68","author":"Souery","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110480_bb0275","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/JCP.0b013e3182228619","article-title":"Switching antidepressant class does not improve response or remission in treatment-resistant depression","volume":"31","author":"Souery","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110480_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001403","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes","volume":"10","author":"Spielmans","year":"2013","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110480_bb0285","first-page":"180","article-title":"Adjunctive therapy with second-generation antipsychotics: the new standard for treatment-resistant depression?","volume":"14","author":"Thase","year":"2016","journal-title":"Focus (Am. Psychiatr. Publ.)"},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110480_bb0290","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11920-016-0715-0","article-title":"Suicidal behavior in mood disorders: response to pharmacological treatment","volume":"18","author":"Tondo","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.pnpbp.2021.110480_bb0295","doi-asserted-by":"crossref","first-page":"110425","DOI":"10.1016\/j.pnpbp.2021.110425","article-title":"Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study","volume":"112","author":"Tundo","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110480_bb0300","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","article-title":"Side effects of atypical antipsychotics: a brief overview","volume":"7","author":"Ucok","year":"2008","journal-title":"World Psychiatry"},{"issue":"10053","key":"10.1016\/j.pnpbp.2021.110480_bb0305","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Vos","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110480_bb0310","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4068\/cmj.2016.52.3.159","article-title":"Second generation antipsychotics in the treatment of major depressive disorder: an update","volume":"52","author":"Wang","year":"2016","journal-title":"Chonnam. Med. J."},{"key":"10.1016\/j.pnpbp.2021.110480_bb0315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fpsyt.2019.00129","article-title":"The association between the sedative loads and clinical severity indicators in the first-onset major depressive disorder","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110480_bb0320","series-title":"SKID-I, Strukturiertes Klinisches Interview f\u00fcr DSM-IV","author":"Wittchen","year":"1997"},{"issue":"11","key":"10.1016\/j.pnpbp.2021.110480_bb0325","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv060","article-title":"Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis","volume":"18","author":"Zhou","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.pnpbp.2021.110480_bb0330","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584621002396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584621002396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:58:12Z","timestamp":1759521492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584621002396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":66,"alternative-id":["S0278584621002396"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110480","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110480"}}